Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Inclusion Criteria

• Inclusion Criteria: AIM-HN 1. At least 18 years of age. 2. Histologically confirmed head and neck cancer (oral cavity, pharynx, larynx, sinonasal, nasopharyngeal, or unknown primary) of squamous histology not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy). 3. Documented treatment failure from most recent prior therapy (e.g. tumor progression, clinical deterioration, or recurrence), and from at least one prior platinum-containing regimen, in any treatment setting. 4. Known tumor missense HRAS mutation. 5. Measurable disease by RECIST v1.1. 6. ECOG performance status of 0-1. 7. Acceptable liver, renal and hematological function 8. Other protocol defined inclusion criteria may apply. Exclusion Criteria: 1. Histologically confirmed salivary gland, thyroid, (primary) cutaneous squamous or nonsquamous histologies (e.g. mucosal melanoma). 2. Received treatment for unstable angina within prior year, myocardial infarction within the prior year, cerebro-vascular attack within the prior year, history of New York Heart Association grade III or greater congestive heart failure, or current serious cardiac arrhythmia requiring medication except atrial fibrillation. 3. Non-tolerable Grade 2 or ≥ Grade 3 neuropathy or evidence of unstable neurological symptoms within 4 weeks of Cycle 1 Day 1. 4. Active, uncontrolled bacterial, viral or fungal infections requiring systemic therapy. Known history of infection with human immunodeficiency virus or an active infection with hepatitis B or hepatitis C. 5. Received treatment for non-cancer related liver disease within prior year. 6. Other protocol defined exclusion criteria may apply Inclusion Criteria: SEQ-HN 1. At least 18 years of age. 2. Histologically confirmed head and neck cancer (oral cavity, pharynx, larynx, sinonasal, nasopharyngeal, or unknown primary) of squamous histology. 3. Will or has received at least one systemic anti-cancer therapy for recurrent or metastatic HNSCC. 4. HRAS wildtype (i.e., have no identified tumor missense HRAS mutation). 5. Other protocol defined inclusion criteria may apply Exclusion Criteria: SEQ-HN 1. Histologically confirmed salivary gland, thyroid, (primary) cutaneous squamous or nonsquamous histologies (e.g. mucosal melanoma). 5. Other protocol defined exclusion criteria may apply